解锁亡途径:在CAR-T细胞疗法中克服瘤抵抗
Zhanna Zhang1, Manqi Su1, Panruo Jiang1
1Department of Hematology, Dongyang Hospital Affiliated to WenZhou Medical University, Jinhua, Zhejiang, China.
Cancer medicine
|October 8, 2024
概括
化学抗原受体 (CAR) -T细胞疗法显示出希望,但耐药性是一个挑战. 本综述探讨了针对亡途径的策略,以提高CAR-T细胞的疗效并克服癌症抵抗力.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 细胞生物学 细胞生物学
背景情况:
- 化学抗原受体 (CAR) -T细胞疗法已经彻底改变了癌症治疗.
- 治疗耐药性仍然是一个重要的障碍,限制了患者的治疗结果.
研究的目的:
- 审查CAR-T细胞治疗中的挑战.
- 专注于亡途径在克服抵抗中的作用.
主要方法:
- 检查使瘤细胞对CAR-T介导的亡敏感的策略.
- 研究组合疗法 (BH3模仿剂,Mcl-1,IAP,HDAC抑制剂).
- 探索新的CAR构造和向瘤微环境 (TME).
主要成果:
- 抑制抗亡蛋白质可以增强瘤细胞的亡.
- 准外部通路会增加死亡受体的表达.
- 新的CAR结构和TME调制可以提高效率.
结论:
- 增强瘤细胞亡和CAR-T细胞细胞毒性是改善结果的关键.
- 向食性蛋白质提供了一种克服抗性的新策略.
- 这一综述为优化CAR-T细胞疗法提供了基础.
相关概念视频
Tumor Immunotherapy
489
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
489
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
The Intrinsic Apoptotic Pathway
6.4K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.4K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
The Extrinsic Apoptotic Pathway
6.3K
The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...
6.3K


